title: Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis.
abstract: OBJECTIVE
  The aim of this study is to compare the effects of hypoglycemic treatments in groups of patients categorized according to the mean baseline body mass indexes (BMIs).
  
  
  METHODS
  Studies were identified by a literature search and all the studies were double blind, placebo-controlled randomized trials in type 2 diabetes patients; study length of ≥12 weeks with the efficacy evaluated by changes in HbA1c from baseline in groups. The electronic search was first conducted in January 2015 and repeated in June 2015.
  
  
  RESULTS
  227 studies were included. Treatment with sulfonylureas was compared with placebo in overweight patients and resulted in a significantly greater change in the HbA1c levels (weighted mean difference (WMD), -1.39%) compared to obese patients (WMD, -0.77%)(p<0.05). Treatment with metformin in overweight patients resulted in a comparable change in the HbA1c levels (WMD, -0.99%) compared to obese patients (WMD, -1.06%)(p>0.05). Treatment with alpha glucosidase inhibitors in normal weight patients was associated with a HbA1c change (WMD, -0.94%) that was comparable that in overweight (WMD, -0.72%) and obese patients (WMD, -0.56%)(p>0.05). Treatment with thiazolidinediones in normal weight patients was associated with a HbA1c change (WMD, -1.04%) that was comparable with that in overweight (WMD, -1.02%) and obese patients (WMD, -0.88%)(p>0.05). Treatment with DPP-4 inhibitors in normal weight patients was associated with a HbA1c change (WMD, -0.93%) that was comparable with that in overweight (WMD, -0.66%) and obese patients (WMD, -0.61%)(p>0.05). In total, of the seven hypoglycemic agents, regression analysis indicated that the mean baseline BMI was not associated with the mean HbA1c changes from baseline.
  
  
  CONCLUSIONS
  In each kind of hypoglycemic therapy in type 2 diabetes, the baseline BMI was not associated with the efficacy of HbA1c changes from baseline.
authors.affiliation: Peking University People's Hospital, Endocrine & Metabolism Department, Beijing, China.
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Cai
authors.affiliation: Peking University People's Hospital, Endocrine & Metabolism Department, Beijing, China.
authors.forename: Wenjia
authors.initials: W
authors.lastname: Yang
authors.affiliation: Peking University People's Hospital, Endocrine & Metabolism Department, Beijing, China.
authors.forename: Xueying
authors.initials: X
authors.lastname: Gao
authors.affiliation: Peking University People's Hospital, Endocrine & Metabolism Department, Beijing, China.
authors.forename: Lingli
authors.initials: L
authors.lastname: Zhou
authors.affiliation: Peking University People's Hospital, Endocrine & Metabolism Department, Beijing, China.
authors.forename: Xueyao
authors.initials: X
authors.lastname: Han
authors.affiliation: Peking University People's Hospital, Endocrine & Metabolism Department, Beijing, China.
authors.forename: Linong
authors.initials: L
authors.lastname: Ji
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000145:classification / Q000627:therapeutic use*; D009765:Obesity / Q000150:complications; D050177:Overweight / Q000150:complications; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents